Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.60 |
| ▸ | CALCR | P30988 | 5/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.56 |
| ▸ | NPY2R | P49146 | 7/20 | 0.56 |
| ▸ | NPY4R | P50391 | 7/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.56 |
| ▸ | NPY1R | P25929 | 5/20 | 0.56 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.55 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.55 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972922 | 0.91 | MAPK8 (0.53) | MAPK8MAPK9MAPK10CALCRNPY2R | |
| SCHEMBL29546394 | 0.91 | CALCR (0.56) | MAPK8MAPK9MAPK10CALCRNPY2R | |
| SCHEMBL31182755 | 0.90 | CALCR (0.60) | MAPK8MAPK9MAPK10CALCRNPY2R | |
| SCHEMBL29607011 | 0.89 | APLNR (0.58) | MAPK8MAPK9MAPK10CALCROPRM1 | |
| SCHEMBL31182765 | 0.89 | CALCR (0.62) | MAPK8MAPK9MAPK10CALCRNPY2R | |
| SCHEMBL29949425 | 0.88 | CALCR (0.67) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30950135 | 0.88 | CALCR (0.57) | MAPK8MAPK9MAPK10CALCRNPY2R | |
| SCHEMBL30607274 | 0.88 | MAPK8 (0.59) | MAPK8MAPK9MAPK10CALCRNPY2R | |
| SCHEMBL29649209 | 0.87 | CALCR (0.67) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29828490 | 0.86 | C5AR1 (0.56) | MAPK8MAPK9MAPK10CALCRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727937-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | Vivoryon Therapeutics N.V. (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | claimed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | claimed |
| US-20250026738-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2025-01-23 | — | — | US | claimed |
| WO-2024256618-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2024-12-19 | — | — | WO | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | claimed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | claimed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | claimed |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-08-28 | — | — | US | claimed |
| WO-2008065141-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-06-05 | — | — | WO | claimed |
| WO-2008055947-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | claimed |
| WO-2008055945-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | claimed |
| WO-2008055950-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-1651169-A4 | COMBINATION THERAPIES FOR MULTIPLE SCLEROSIS | MEDAREX INC (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | claimed |
| EP-1651169-A2 | COMBINATION THERAPIES FOR MULTIPLE SCLEROSIS | Ability Biomedical Corporation (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011605-A2 | COMBINATION THERAPIES FOR MULTIPLE SCLEROSIS | MEDAREX, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050025744-A1 | Combination therapies for multiple sclerosis | LANE THOMAS E (US) | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | MAPK8 3884/4885MAPK9 3337/4885MAPK10 3452/4885 |
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | MAPK8 2532/4885MAPK9 3231/4885MAPK10 2392/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | MAPK8 1831/4885MAPK9 1528/4885MAPK10 1943/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | MAPK8 1710/4885MAPK9 1461/4885MAPK10 2149/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | MAPK8 2139/4885MAPK9 1945/4885MAPK10 1710/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | MAPK8 4235/4885MAPK9 3717/4885MAPK10 3929/4885 |
| US-20250026738-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | QPCT, GLS, QPCTL | MAPK8 3175/4885MAPK9 2466/4885MAPK10 2693/4885 |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | MAPK8 3952/4885MAPK9 3988/4885MAPK10 3422/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | MAPK8 3606/4885MAPK9 3061/4885MAPK10 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.